Genetic Signatures Ltd
ASX:GSS
Net Margin
Genetic Signatures Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Genetic Signatures Ltd
ASX:GSS
|
72.7m AUD |
-123%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
996.9B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
184B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.6B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
72.9T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.8B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
269.7B CNY |
32%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.5B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32.7B USD |
8%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.3B USD |
21%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.3B EUR |
8%
|
Genetic Signatures Ltd
Glance View
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Genetic Signatures Ltd's most recent financial statements, the company has Net Margin of -122.7%.
You don't have any saved screeners yet